receive artificial tears drop

Small molecule

SShahid Beheshti University of Medical Sciences

receive artificial tears drop is one of 27 small molecule programs targeting Retinopathy of Prematurity. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinopathy of PrematurityActive, not recruiting

Retinopathy of PrematurityPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Retinopathy of Prematurity

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

1 2

Advil

KKenvue Brands

Approved

1 3

Lucentis

Roche

Phase 3

4 4

Decadron

AAspen Global Incorporated

Eylea

3 6

Avastin

BBio-Thera Solutions

Phase 3

7 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Eylea

Bayer

Phase 3

1 9

Inderal

WWyeth-Lederle Vaccines

Phase 2

5 10

Smoflipid

FFresenius

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinopathy of Prematurity1 trial

Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT04191954·184 enrolled

Bevacizumab1 trial

Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 2·NCT04800679·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for receive artificial tears drop. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — receive artificial tears drop compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for receive artificial tears drop. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shahid Beheshti University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SShahid Beheshti University of Medical Sciences

receive artificial tears drop

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinopathy of Prematurity1 trial

Bevacizumab1 trial

References

Drug Info

Quick Facts

Related News